Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Department of Dermatology, PEDEGO Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
J Invest Dermatol. 2019 Apr;139(4):755-756. doi: 10.1016/j.jid.2018.11.025.
The study by Plaquevent et al. strongly supports the recent discovery that the use of gliptins is a risk factor for bullous pemphigoid (BP). However, regarding the phenotype of gliptin-associated BP and the necessity of gliptin withdrawal, clinical data remain scarce. We predict that future studies of gliptin-associated BP will offer valuable information concerning autoimmunity against BP180 and may also shed light on the pathology of autoimmune diseases in general.
Plaquevent 等人的研究有力地支持了最近的发现，即使用gliptins 是大疱性类天疱疮 (BP) 的一个风险因素。然而，关于gliptin 相关性 BP 的表型和是否需要停止使用gliptin，临床数据仍然很少。我们预测，未来对 gliptin 相关性 BP 的研究将提供有关针对 BP180 的自身免疫的有价值的信息，并可能为一般自身免疫性疾病的病理学提供一些线索。
